Portfolio
Portfolio

Bluebird Bio

Innovative gene therapies for severe genetic disorders from a broadly applicable gene therapy platform.

Bluebird Bio is developing innovative gene therapies for severe genetic disorders from a broadly applicable gene therapy platform. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/ sickle cell anemia. The company was formerly known as Genetix Pharmaceuticals.

  • CEO Nick Leshly
  • Industry Biotech
  • History IPO